Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Rifampicin-Resistant Pulmonary Tuberculosis
View Full LandscapeTarget Indication
Rifampicin-Resistant Pulmonary Tuberculosis
Clinical Trial
NCT07209761Last updated: 10/27/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Dovprela (previously Pretomanid FGK)
Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
